TrkB promotes breast cancer metastasis via suppression of Runx3 and Keap1 expression

Molecules and Cells

Volumn 39, Issue 3, 2016, Pages 258-265

  Kim, Min Soo ^a   Lee, Won Sung ^a   Jin, Wook ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Breast cancer; Keap1; Metastasis; Runx3; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR RUNX3; KEAP1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ARTICLE; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; METASTATIC BREAST CANCER; PHENOTYPE; PI3K/AKT SIGNALING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 85017046197     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2016.2310     Document Type: Article

References (40)

1. Bardelli, A., Parsons, D.W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J.K., Parmigiani, G., Kinzler, K.W., et al. (2003). Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949.
2. Cancer Genome Atlas, N. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
3. Chao, M.V., and Bothwell, M. (2002). Neurotrophins: to cleave or not to cleave. Neuron 33, 9-12.
4. Chen, L.F. (2012). Tumor suppressor function of RUNX3 in breast cancer. J. Cell Biochem. 113, 1470-1477.
5. Chi, X.Z., Yang, J.O., Lee, K.Y., Ito, K., Sakakura, C., Li, Q.L., Kim, H.R., Cha, E.J., Lee, Y.H., Kaneda, A., et al. (2005). RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor (Bierie and Moses)-activated SMAD. Mol. Cell Biol. 25, 8097-8107.
6. Dai, B., Yoo, S.Y., Bartholomeusz, G., Graham, R.A., Majidi, M., Yan, S., Meng, J., Ji, L., Coombes, K., Minna, J.D., et al. (2013). KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 73, 5532-5543.
7. DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109.
8. Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D.M., Morgan, M.B., et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075.
9. Dionne, C.A., Camoratto, A.M., Jani, J.P., Emerson, E., Neff, N., Vaught, J.L., Murakata, C., Djakiew, D., Lamb, J., Bova, S., et al. (1998). Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. 4, 1887-1898.
10. Douma, S., Van Laar, T., Zevenhoven, J., Meuwissen, R., Van Garderen, E., and Peeper, D. S. (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034-1039.
11. Eades, G., Yang, M., Yao, Y., Zhang, Y., and Zhou, Q. (2011). miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J. Biol. Chem. 286, 40725-40733.
12. Eggert, A., Grotzer, M.A., Ikegaki, N., Zhao, H., Cnaan, A., Brodeur, G. M., and Evans, A. E. (2001). Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms’ tumor. J. Clin. Oncol. 19, 689-696.
13. Geiger, T.R., and Peeper, D.S. (2005). The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res. 65, 7033-7036.
14. Goh, Y.M., Cinghu, S., Hong, E.T., Lee, Y.S., Kim, J.H., Jang, J.W., Li, Y.H., Chi, X.Z., Lee, K.S., Wee, H., et al. (2010). Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J. Biol. Chem. 285, 10122-10129.
15. Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., Ishiguro, A., Kijima, H., Mimura, J., Itoh, K., et al. (2012). Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 12, 66.
16. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
17. Hartikainen, J.M., Tengstrom, M., Winqvist, R., Jukkola-Vuorinen, A., Pylkas, K., Kosma, V.M., Soini, Y., and Mannermaa, A. (2015). KEAP1 genetic polymorphisms associate with breast cancer risk and survival outcomes. Clin. Cancer Res. 21, 1591-1601.
18. Hartwell, K.A., Muir, B., Reinhardt, F., Carpenter, A.E., Sgroi, D.C., and Weinberg, R.A. (2006). The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc. Natl. Acad. Sci. USA 103, 18969-18974.
19. Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116-4124.
20. Huang, B., Qu, Z., Ong, C. W., Tsang, Y. H., Xiao, G., Shapiro, D., Salto-Tellez, M., Ito, K., Ito, Y., and Chen, L.F. (2012). RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 31, 527-534.
21. Jaramillo, M.C., and Zhang, D.D. (2013). The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179-2191.
22. Jin, W., Kim, G.M., Kim, M.S., Lim, M.H., Yun, C., Jeong, J., Nam, J.S., and Kim, S.J. (2010). TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 31, 1939-1947.
23. Ke, B., Shen, X.D., Zhang, Y., Ji, H., Gao, F., Yue, S., Kamo, N., Zhai, Y., Yamamoto, M., Busuttil, R.W., et al. (2013). KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J. Hepatol. 59, 1200-1207.
24. Kim, M. S., Lee, W. S., Jeong, J., Kim, S. J., and Jin, W. (2015). Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget 6, 40158-40171.
25. Knusel, B., and Hefti, F. (1992). K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem. 59, 1987-1996.
26. Koizumi, S., Contreras, M. L., Matsuda, Y., Hama, T., Lazarovici, P., and Guroff, G. (1988). K-252a: a specific inhibitor of the action of nerve growth factor on PC 12 cells. J. Neurosci. 8, 715-721.
27. Lee, Y.S., Lee, J.W., Jang, J.W., Chi, X.Z., Kim, J.H., Li, Y.H., Kim, M.K., Kim, D.M., Choi, B.S., Kim, E.G., et al. (2013). Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24, 603-616.
28. Lin, F.C., Liu, Y.P., Lai, C.H., Shan, Y.S., Cheng, H.C., Hsu, P.I., Lee, C.H., Lee, Y.C., Wang, H.Y., Wang, C.H., et al. (2012). RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene 31, 4302-4316.
29. Lu, J., Guo, H., Treekitkarnmongkol, W., Li, P., Zhang, J., Shi, B., Ling, C., Zhou, X., Chen, T., Chiao, P.J., et al. (2009). 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelialmesenchymal transition. Cancer Cell 16, 195-207.
30. Ma, X.J., Salunga, R., Tuggle, J.T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B.M., et al. (2003). Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA 100, 5974-5979.
31. Marchetti, A., Felicioni, L., Pelosi, G., Del Grammastro, M., Fumagalli, C., Sciarrotta, M., Malatesta, S., Chella, A., Barassi, F., Mucilli, F., et al. (2008). Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum. Mutat. 29, 609-616.
32. Miknyoczki, S.J., Dionne, C.A., Klein-Szanto, A.J., and Ruggeri, B.A. (1999). The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann. N Y Acad. Sci. 880, 252-262.
33. Rizvi, F., Shukla, S., and Kakkar, P. (2014). Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3beta/Fyn kinase axis during oxidative hepatocellular toxicity. Cell Death Dis. 5, e1153.
34. Scheel, C., Eaton, E.N., Li, S.H., Chaffer, C.L., Reinhardt, F., Kah, K.J., Bell, G., Guo, W., Rubin, J., Richardson, A.L., et al. (2011). Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940.
35. Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., and Hirohashi, S. (2008). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358-1368, 1368 e1351-1354.
36. Smit, M.A., and Peeper, D.S. (2011). Zeb1 is required for TrkBinduced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 30, 3735-3744.
37. van de Vijver, M.J., He, Y.D., van’t Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M. J., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl. J. Med. 347, 1999-2009.
38. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R.A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
39. Yilmaz, T., Jiffar, T., de la Garza, G., Lin, H., Milas, Z., Takahashi, Y., Hanna, E., MacIntyre, T., Brown, J.L., Myers, J.N., et al. (2010). Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol. Ther. 10, 644-653.
40. Zhang, S., Guo, D., Luo, W., Zhang, Q., Zhang, Y., Li, C., Lu, Y., Cui, Z., and Qiu, X. (2010). TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer 10, 43.